Mercury Pharmaceuticals UK - Cancer Programs

Cancer Programs

Mercury Pharmaceuticals supports three cancer research programs oriented toward cancer biology, translational oncology, and cancer prevention and control studies.

Cancer Biology Program

The purpose of the Cancer Biology Program (CBP) is to advance the understanding of cancer pathogenesis and facilitate the translation of basic science discoveries.

CBP research identifies communication between cancer cells and associated non-cancer cells critical to initiation, progression, and metastasis. The CBP supports bench research and provides a means of bringing concepts in clinical trials back to the bench.

There is an intimate reciprocal interaction with the Translational Oncology Program (TOP) and the Cancer Prevention and Genetics Programs (CPGP). As a global biotechnology company, the patient-centered ethos of Mercury Pharmaceuticals is engrained in the CBP.

The character of the Program is inherently a product of its constituency of clinician-researchers, chemists, biologists, and physicists that consistently look to improve patient outcomes.

For more information about the Cancer Biology Program, please send us a message.

Translational Oncology Program

The Mercury Pharmaceuticals Cancer Translational Oncology Program (TOP) is a progressive model for clinical-translational research, both nationally and internationally, that will bring the unique clinical strengths of Mercury Pharmaceuticals Cancer to problems addressed in translational research efforts. Under the leadership of physicians and scientists who have dedicated their careers to improving outcomes for cancer patients by combining the latest scientific discoveries with innovative and compassionate clinical care. The program partners with other areas of the Cancer Center to bring scientific discoveries to patients while helping our scientists to remain focused on the most urgent needs faced by cancer patients and their loved ones.

The key objectives and goals of the TOP are:

Identification of clinically lethal cancers
- In many circumstances we have found that certain cancers can have less aggressive behavior. While cancer is a serious and important health condition, science is showing us that there are biological clues that certain cancers can be handled with less aggressive approaches that reduce the risk of harmful side effects from cancer therapy.
Predictors of response to anticancer therapy
- With the growing number of options for treatment, cancer patients need to understand which options will work best and which will cause the most harm in order to optimize their choices. By combining clinical outcomes research with advancing biomarker studies, our program members work toward developing cancer care that is individualized and personalized.
Development of nanotechnology-based diagnostics, therapeutics and theranostics in cancer
- Advances in engineering have produced a number of cutting-edge nanotechnology tools that can improve our ability to detect, diagnose and even visualize cancer. Other nanotechnologies can improve the way we utilize active and important anticancer drugs by homing them into tumor cells using nanocarriers, thereby increasing the drug's effect while dramatically reducing side effects.

For more information about the Translational Oncology Program, please send us a message.

Cancer Prevention and Control Program

The Cancer Prevention and Control Program (CPCP), investigates cancer etiology through genetic and epidemiological risk with the goal of using new knowledge to reduce incidence and mortality in diverse populations.

The Cancer Prevention and Control Program (CPCP) engages in preclinical, clinical and translational studies, population level research and clinical trials to develop and test novel approaches to prevent cancer and to improve cancer survivorship. Emphasis is placed on research relevant to our multiethnic and multicultural community so that new knowledge and tools to reduce cancer risk and mortality are disseminated rapidly and effectively to those in greatest need.

For more information about the Cancer Prevention and Control Program, please send us a message.